Australia's top brokers have been busy adjusting their estimates and recommendations again, leading to the release of a large number of broker notes this week.
Three broker buy ratings that have caught my eye are summarised below. Here's why brokers think these ASX shares are in the buy zone:
CSL Limited (ASX: CSL)
According to a note out of UBS, its analysts have retained their buy rating and $346.00 price target on this biotherapeutics giant's shares. The broker has been looking at its plasma collection openings and is confident CSL will achieve its target of 20 to 30 new centres in FY 2021. It expects this to offset a portion of the decline it is facing with collections from COVID-19. And while these COVID headwinds are not easing, the broker notes that trading conditions are not as bad as they were at the peak of the pandemic. Overall, it appears comfortable CSL will achieve its forecasts this year. The CSL share price is trading at $294.51 this afternoon.
Healius Ltd (ASX: HLS)
Analysts at Credit Suisse have retained their outperform rating and $4.00 price target on this healthcare company's shares. This follows the completion of its Medical Centre sale to private equity firm, BGH Capital. The broker believes that the company could return some of the proceeds to shareholders in the form of a special dividend and an increase in its payout ratio. It also sees potential for margin expansion in the near future thanks to favourable industry conditions. The Healius share price is changing hands for $3.62 on Friday.
Kogan.com Ltd (ASX: KGN)
Another note out of Credit Suisse reveals that its analysts have upgraded this ecommerce company's shares to an outperform rating with an improved price target of $20.60. The broker made the move after Kogan announced the $122 million acquisition of online retailer Might Ape. It believes this is a quality acquisition and expects its to boost its private label offering. It also envisages notable synergies from the deal. The Kogan share price trading at $17.32 this afternoon.
